Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
CME|Podcasts|August 17, 2026
Key Considerations for Health Equity and Patient-Centered Care in TNBC
OncLive On Air®
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Aditya Bardia, MD, MPH, FASCO, and Kathryn E. Post, PhD, ANP-BC, discuss key drivers of disparities in outcomes for triple-negative breast cancer and strategies for patient-centered communication, from shared decision-making to managing treatment-related toxicity.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Faculty:
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine, Geffen School of Medicine
University of California, Los Angeles
Program Director, Breast Medical Oncology
Assistant Chief of Translational Research, Division of Hematology-Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Kathryn E. Post, PhD, ANP-BC
Advanced Practice Provider Scholar
Mass General Brigham Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA
This podcast, including the narration, was produced by the PER® editorial staff based on an online activity conducted with these faculty members. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on first-line treatment selection with antibody-drug conjugates in metastatic triple-negative breast cancer, go to
Release Date
August 17, 2026
Expiration Date
August 17, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Related to this article
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
A UCLA study found that traditional pathological features do not predict who will benefit more from adding hormone therapy to postoperative radiation.
New research explains what triggers liposarcoma cells to become more or less aggressive and identifies potential targets for aggressive tumors.
UCSF Health’s Adam Blaisdell, MD, PhD, has been selected as an IGNITE fellow by the Cancer Research Institute.
Huntsman Cancer Institute received recent national honors, recognizing excellence in cancer care, research, nursing, and healing-centered facilities.
Colorectal cancer is not the only gastrointestinal cancer that doctors are diagnosing in patients below the age of 50.
New insights on early detection, cancer biology and surgical innovation in head and neck cancer highlighted at international research meeting.
Trending on OncLive
1
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
2
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
3
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
5